A detailed history of Jacobs Levy Equity Management, Inc transactions in Incyte Corp stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 92,782 shares of INCY stock, worth $7.21 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
92,782
Previous 155,495 40.33%
Holding current value
$7.21 Million
Previous $9.43 Million 34.95%
% of portfolio
0.02%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $3.6 Million - $4.3 Million
-62,713 Reduced 40.33%
92,782 $6.13 Million
Q2 2024

Aug 14, 2024

SELL
$51.18 - $63.75 $121 Million - $150 Million
-2,359,139 Reduced 93.82%
155,495 $9.43 Million
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $10.1 Million - $11.8 Million
177,852 Added 7.61%
2,514,634 $143 Million
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $13.1 Million - $16.1 Million
251,317 Added 12.05%
2,336,782 $147 Million
Q3 2023

Nov 16, 2023

BUY
$57.77 - $65.93 $18.1 Million - $20.7 Million
313,731 Added 17.71%
2,085,465 $120 Million
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $6.31 Million - $7.82 Million
103,516 Added 6.21%
1,771,734 $110 Million
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $23.8 Million - $29.1 Million
338,311 Added 25.44%
1,668,218 $121 Million
Q4 2022

Feb 14, 2023

BUY
$67.18 - $84.11 $11.7 Million - $14.6 Million
173,622 Added 15.02%
1,329,907 $107 Million
Q3 2022

Nov 15, 2022

BUY
$66.18 - $82.86 $1.51 Million - $1.89 Million
22,753 Added 2.01%
1,156,285 $77.1 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $1.28 Million - $1.61 Million
-19,339 Reduced 1.68%
1,133,532 $86.1 Million
Q1 2022

May 16, 2022

BUY
$66.02 - $79.71 $5.03 Million - $6.07 Million
76,180 Added 7.08%
1,152,871 $91.6 Million
Q4 2021

Feb 14, 2022

SELL
$63.34 - $74.11 $3.1 Million - $3.63 Million
-48,964 Reduced 4.35%
1,076,691 $79 Million
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $7.65 Million - $9.36 Million
111,392 Added 10.98%
1,125,655 $77.4 Million
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $18.1 Million - $19.8 Million
226,110 Added 28.69%
1,014,263 $85.3 Million
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $10.3 Million - $13.6 Million
135,415 Added 20.75%
788,153 $64.1 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $6.09 Million - $7.37 Million
75,469 Added 13.07%
652,738 $56.8 Million
Q3 2020

Nov 16, 2020

BUY
$85.07 - $109.69 $16.5 Million - $21.2 Million
193,571 Added 50.45%
577,269 $51.8 Million
Q2 2020

Aug 17, 2020

SELL
$74.18 - $108.93 $27.8 Million - $40.9 Million
-375,100 Reduced 49.43%
383,698 $39.9 Million
Q1 2020

May 15, 2020

BUY
$63.18 - $85.97 $7.25 Million - $9.86 Million
114,711 Added 17.81%
758,798 $55.6 Million
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $20.5 Million - $26.9 Million
280,937 Added 77.36%
644,087 $56.2 Million
Q3 2019

Nov 14, 2019

BUY
$72.82 - $86.52 $12 Million - $14.3 Million
164,703 Added 83.0%
363,150 $27 Million
Q2 2019

Aug 13, 2019

SELL
$73.52 - $88.7 $7.37 Million - $8.89 Million
-100,233 Reduced 33.56%
198,447 $16.9 Million
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $5.99 Million - $8.32 Million
94,320 Added 46.15%
298,680 $25.7 Million
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $7 Million - $8.37 Million
119,630 Added 141.19%
204,360 $13 Million
Q3 2018

Nov 14, 2018

BUY
$61.75 - $74.23 $1.32 Million - $1.58 Million
21,340 Added 33.66%
84,730 $5.85 Million
Q2 2018

Aug 14, 2018

BUY
$60.85 - $83.98 $3.86 Million - $5.32 Million
63,390 New
63,390 $4.25 Million
Q1 2018

May 15, 2018

SELL
$83.06 - $100.98 $183,562 - $223,165
-2,210 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $241,221 - $305,576
2,210
2,210 $258,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $17.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.